In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

SkyePharma and Novartis develop asthma and COPD treatment

Executive Summary

SkyePharma PLC will apply its SkyeHaler and SkyeProtect drug delivery technologies to Novartis's long-acting bronchodilator QAB149 to develop a new product for asthma and chronic obstructive pulmonary disease (COPD).
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register